IPI-145 (duvelisib)

DRUG3 trials

Sponsors

SecuraBio

Conditions

HealthyHematologic MalignanciesLymphocytic Leukemia, ChronicLymphoma, Small Lymphocytic

Phase 1

A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies

TerminatedNCT01476657

SecuraBioHematologic Malignancies

Start: 2011-10-31End: 2017-01-31Updated: 2021-03-17

Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

TerminatedNCT02292225

SecuraBioLymphocytic Leukemia, Chronic, Lymphoma, Small Lymphocytic

Start: 2015-02-28End: 2016-11-30Updated: 2023-02-27

Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145

CompletedNCT02307461

SecuraBioHealthy

Start: 2014-11-30End: 2015-09-30Updated: 2021-03-17

Related Papers

Characterization of the Long-Term Efficacy and Safety of Duvelisib Monotherapy in Patients with Relapsed/Refractory CLL/SLL on Treatment for > 2 Years across 4 Clinical Studies

Blood2018-11-291 citations

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Blood2017-12-12274 citations

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

Blood2017-11-30250 citations

Early clinical activity and pharmacodynamic effects of duvelisib, a PI3K-δ,γ inhibitor, in patients with treatment-naïve CLL.

Journal of Clinical Oncology2015-05-2011 citations

Serum chemokines and cytokines in CLL patients treated with duvelisib, a PI3K-δ,γ inhibitor.

Journal of Clinical Oncology2015-05-202 citations

A phase 1b trial of duvelisib, a PI3K-δ,γ inhibitor, in combination with obinutuzumab in patients with CLL/SLL previously treated with a Bruton’s tyrosine kinase inhibitor (BTKi).

Journal of Clinical Oncology2015-05-202 citations

Preliminary Safety and Efficacy Of IPI-145, a Potent Inhibitor Of Phosphoinositide-3-Kinase-δ,γ, In Patients With Chronic Lymphocytic Leukemia

Blood2013-11-1528 citations

The Potent PI3K-δ,γ Inhibitor IPI-145 Exhibits Differential Activity In Diffuse Large B-Cell Lymphoma (DLBCL) Cell Lines

Blood2013-11-157 citations

The Potent PI3K-δ,γ Inhibitor, IPI-145, Exhibits Preclinical Activity In Murine and Human T-Cell Acute Lymphoblastic Leukemia

Blood2013-11-154 citations

Treatment With The Potent PI3K-δ,γ Inhibitor IPI-145 Is Associated With Rapid Decreases In Specific Cytokines, Chemokines and Matrix Metalloproteinases In The Serum Of Patients With Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma

Blood2013-11-153 citations